Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jul 6, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging tool called fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) to help doctors see and assess the extent of Non-Small Cell Lung Cancer (NSCLC) in patients, particularly those with brain metastases (cancer that has spread to the brain). The researchers believe that this imaging method, combined with a standard scan called Positron Emission Tomography (PET) and Computed Tomography (CT), can provide clearer information about the disease, which may help in planning further treatment.

To participate in this trial, individuals must be over 18 years old and have a confirmed diagnosis of NSCLC that has spread to the brain, whether or not it has already been treated. Participants should be able to undergo the required imaging procedures, which may last between 30 to 60 minutes. They will also need to have certain health checks done within a few weeks before joining the study. It’s important to note that pregnant women, prisoners, and those with specific other health conditions are not eligible for this trial. If you or a loved one is interested, the study is currently recruiting participants and aims to provide valuable insights into more effective cancer imaging.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women age \>18 yrs
• • 2. Biopsy proven NSCLC with brain metastases (treated or untreated)
• • 3. Life-expectancy of ≥3 months in the opinion of the treating physician
• • 4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
• • 5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
• • 6. Ability to understand and willingness to sign a written informed consent document.
• • 7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
• • 8. \[18F\]-FDG PET/CT within 21 days of enrollment
• • 9. MRI brain within 21 days of enrollment
• • 10. Eastern Cooperative Oncology Group Performance Status ≤ 2
• • 11. Glomerular filtration rate (GFR) ≥ 60
• Exclusion Criteria:
• • 1. Pregnant or lactating women
• • 2. Prisoners
• • 3. Concurrent malignancy of a different histology that could confound imaging interpretation
• • 4. Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)